This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Biotech Stocks Expected to at Least Double

2. Cyclacel Pharmaceuticals (CYCC) develops mechanism-targeted drugs for human cancers, targeting the cell cycle in order to slow progression or shrink tumors. Cyclacel's second-quarter loss decreased 44% to $3.9 million, or 18 cents a share, as revenue fell 55%. Cyclacel has $20 million of cash and no debt. Its stock sells for a book value multiple of 4.3, a 19% discount to its peer average. It's expensive based on sales. Just two analysts follow the company, both rating its stock "buy." A median target of $5.25 suggests the stock will more than triple.

Bullish Scenario: Roth Capital Partners values the stock at $7, implying it will more than quadruple.
9 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
AAPL $110.53 -1.60%
FB $88.24 -1.80%
GOOG $607.50 -1.10%
TSLA $246.27 -0.57%
YHOO $32.54 2.40%


Chart of I:DJI
DOW 16,392.30 +40.92 0.25%
S&P 500 1,945.75 -3.11 -0.16%
NASDAQ 4,724.23 -25.7490 -0.54%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs